SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
Manso, Luis (Hospital Universitario 12 de Octubre (Madrid))
Ramchandani-Vaswani, Avinash (Hospital Universitario Insular de Gran Canaria)
Romero, Ignacio (Fundació Institut Valencià d'Oncologia)
Sánchez-Lorenzo, Luisa (Clínica Universidad de Navarra (Madrid))
Bermejo-Pérez, Maria José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Estévez-García, Purificación (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Fariña-Madrid, Lorena (Hospital Universitari Vall d'Hebron)
García García, Yolanda (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Gil-Martin, Marta (Institut Català d'Oncologia)
Quindós, María (Complexo Hospitalario Universitario de Santiago)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cervical cancer ; Guideline ; Diagnosis ; Treatment
Published in:	Clinical & translational oncology, Vol. 26 Núm. 11 (november 2024) , p. 2771-2782, ISSN 1699-3055

DOI: 10.1007/s12094-024-03604-3
PMID: 39215938

12 p, 836.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles